tradmap

RPRX Earnings Royalty Pharma Plc

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
$0 $1 $3 2020 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $1B $2B 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
$0 $1B $2B 2018 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
$0 $1 $1 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $337M $674M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
$0 $272M $544M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–25 of 25
Q2 20262026-06-300.712026-08-0510-Q
Q1 20262026-03-310.672026-05-0610-Q
FY 20252025-12-311.782026-02-1110-K
Q3 20252025-09-301.282025-11-0510-Q
Q2 20262025-06-300.632026-08-0510-Q
Q1 20262025-03-310.552026-05-0610-Q
FY 20252024-12-311.912026-02-1110-K
Q3 20252024-09-301.442025-11-0510-Q
Q2 20252024-06-300.242025-08-0610-Q
Q1 20252024-03-310.012025-05-0810-Q
FY 20252023-12-312.532026-02-1110-K
Q3 20242023-09-301.432024-11-0610-Q
Q2 20242023-06-301.272024-08-0810-Q
Q1 20242023-03-310.762024-05-0910-Q
FY 20242022-12-310.102025-02-1210-K
Q3 20232022-09-301.142023-11-0810-Q
Q2 20232022-06-300.822023-08-0810-Q
Q1 20232022-03-310.122023-05-0910-Q
FY 20232021-12-311.492024-02-1510-K
Q3 20222021-09-301.492022-11-0810-Q
Q2 20222021-06-301.252022-08-0410-Q
Q1 20222021-03-310.182022-05-0510-Q
FY 20222020-12-311.322023-02-1510-K
Q3 20212020-09-300.882021-11-1010-Q
Q2 20212020-06-300.092021-08-1110-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.